This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Shire Human Genetic Therapies, Inc.. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Scott Alderucci: Innovator in Genetic Therapies
Introduction
Scott Alderucci is a notable inventor based in Sutton, MA (US). He has made significant contributions to the field of genetic therapies, particularly in the development of innovative solutions for genetic disorders.
Latest Patents
Alderucci holds a patent for the "Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof." This patent describes isolated nucleic acid molecules that comprise a nucleotide sequence encoding the mannose receptor, C type 1 (MRC1). The 5' region of this nucleotide sequence is codon optimized, which enhances its functionality. The patent also details methods for detecting antibody production, such as neutralizing antibody production, in subjects being treated for Gaucher disease using these specialized cells. He has 1 patent to his name.
Career Highlights
Scott Alderucci is currently employed at Shire Human Genetic Therapies, Inc., where he continues to work on groundbreaking research in genetic therapies. His expertise and innovative approach have positioned him as a valuable asset in the field.
Collaborations
Alderucci collaborates with talented professionals, including Juan Ruiz and Marcia Sellos-Moura, who contribute to his research endeavors and enhance the impact of his work.
Conclusion
Scott Alderucci's contributions to genetic therapies through his innovative patent and collaborative efforts highlight his role as a key figure in advancing medical science. His work continues to pave the way for new treatments for genetic disorders.